18-11-2020
Pavel Kapysh / Shutterstock.com
Daiichi Sankyo and AstraZeneca have asked the US District Court for the District of Delaware for a declaration that their breast cancer treatment does not infringe a chemotherapy patent owned by biotechnology company Seagen.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
AstraZeneca, Daiichi Sankyo, Seagen, breast cancer, patent infringement, biopharmaceutical
PTAB grants review of Seagen patent on eve of court’s infringement ruling
11-04-2022
Pyxis secures ADC licence from Pfizer
22-03-2021
AstraZeneca to buy Alexion for $39bn
14-12-2020
Indian court rejects AstraZeneca’s injunction request
24-11-2020
Seagen targets Daiichi in cancer drug suit
22-10-2020
AstraZeneca and Daiichi Sankyo to jointly develop another new cancer treatment
30-07-2020
